The GAD ELISA is an ELISA test for the measurement of circulating autoantibodies to glutamic acid decarboxylase (GAD-65) antigen in prediabetic high risk individuals as well as IDDM diabetic subjects.


Catalog No Size
Product Catalog No: EIA-1910 Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Test Principle

A purified GAD antigen is immobilized onto microwells. GAD specific IgG antibodies present in the individual’s serum sample are allowed to react with the antigen. The excess /unbound serum proteins are washed-off from the microwells. An enzyme (alkaline phosphatase) labeled goat-antibody, specific to human IgG is added to the GAD antibody complex. After washing off excess unreacted enzyme conjugate from the microwells, a substrate (PNPP) is added and the color generated is measured spectrophotometrically. The intensity of the color developed gives directly the concentration of GAD autoantibodies in the test serum sample. GAD high and low controls serve as an internal quality control to ensure valid result.

Order Enquiry

Order Enquiry Form

References
  • Cooke, A. (1990). An overview on the possible mechanism of destruction of the insulin-producing beta cell. Curr. Top. Microbiol. Immunol. 164:125-142.
  • Harrison, L.C., I.L. Campbell, P.G. Colman, et al (1990). Type 1 diabetes: Immunology and Immunotherapy. Adv. Endocrinol. Metab. 1:35-94.
  • Bottazzo, G.F., A. Florin-Christensen, and D. Doniach (1974). Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet, ii:1279-1283.
  • Colman, P.G., R.C. Nayak, I.L. Campbell, and g.s. Eisenbarth (1988). Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipin extract. Diabetes, 37:645-652.
  • Baekkeskou, S., J.H. Nielson, and B. Marner, et al. (1982). Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature, 298:167-169.
  • Palmer, J.P., C.M. Aspilin, P. Clemons, et al. (1983). Insulin antibodies in insulin-dependent diabetes before insulin treatment. Science, 222:1337—1339.
  • Erlander, M.G. and A. J. Tobin (1991). The structure and functional heterogenicity of glutamic acid decarboxylase: a review. Neurochem. Res., 16:215-226.
  • Bu, D.F., M.G. Erlander, B.C. Hitz, N.J. Tillakaratne, et al. (1992). Two human glutamic decarboxylases, 65- kda GAD and 67-kda GAD, are encoded by a single gene. Proc. Natl. Acad. Sci. USA, 89:2115-2119.
  • Christgau, S., H. Schierbeck, H.J. Aunstoot, L. Aaggard, et al. (1991). Pancreatic B-Cells express two autoantigenic forms of glutamic acid decarboxylase, a 65-kda hydrophilic form and a 64-kda amphiphilic form which can be both membrane-bound and soluble. J. Biol. Chem., 266:21257-21269.
  • Clare-Salzler, M.J., A.J. Tobin, and D.LO. Kaufman (1992). Glutamate decarboxylase: an autoantigen in IDDM. Diabetes Care, 15:132-135.
  • Giorda, R., M. Peakman, K.C. Tan, D. Vergani, and M. Trucco (1991). Clutamic acid decarboxylase expression in islets and brain. Lancet, 338:1469-1470.
  • Kim, J., W. Richter, H.J. Aanstoot, Y. Shi, Q. Fu, et al. (1993). Differential expression of GAD 65 and GAD 67 in humans, rat and mouse pancreatic islets. Diabetes, 42:1799-1808.
  • Dean, B.M., F. Becker, J.M. McNally, A.C. Tarn, et al. (1986). Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes. Diabetologia, 29:339-342.
  • Komalesh, M., A. Karasik, and S. Srikanta (1986). Islet cell antibodies as predictors of insulin-dependent diabetes mellitus. Pract. Cardiol., 12:79-91.
Documents
Enquiry